Navigation Links
Anesiva Commences Phase 2 Trial of Adlea(TM) in Arthroscopic Shoulder Surgery
Date:7/17/2008

at seeks to be the leader in the development and commercialization of novel pharmaceutical products for pain management. The company's first commercial product, Zingo(TM), is available in the U.S. for the reduction of pain associated with peripheral venous access procedures in children ages three to 18.

The next product in Anesiva's pipeline, Adlea(TM), is currently being evaluated in two pivotal Phase 3 clinical trials to support an indication for the management of acute pain following orthopedic surgery. Adlea has been shown to reduce pain after only a single administration for weeks to months in multiple settings in mid-stage clinical trials for site-specific, acute and chronic, moderate-to-severe pain.

Anesiva is based in South San Francisco, CA. For more information about Anesiva's leadership in the development of products for pain management, and an overview of the clinical challenges being addressed by its product candidates, go to http://www.anesiva.com.

Forward Looking Statements

This press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions are intended to identify such forward-looking statements. Forward-looking statements in this press release include matters that involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to differ materially from results expressed or implied by this press release. Such risk factors include, among others: the timing and results of our clinical trials, and our regulatory approval strategy for Adlea. Actual results may differ materially from thos
'/>"/>

SOURCE Anesiva, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Anesiva Announces South Korea FDA Approval of Adlea(TM) Investigational New Drug Application
2. Anesiva Announces Publication of Phase 3 Zingo(TM) Data in the Journal Pediatrics
3. Anesiva Announces Pivotal Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Total Knee Replacement
4. Anesiva Commences Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Bunionectomy
5. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
6. Anesiva Defines Regulatory Pathway for Adlea with FDA
7. Anesiva Initiates Phase 2 Trial with Adlea(TM) for Pain Relief Following Total Hip Replacement Surgery
8. Anesiva Initiates New Phase 2 Trial of Adlea(TM) for Pain Relief Following Knee Replacement Surgery
9. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
10. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
11. EntreMed Commences Continuous Dosing Clinical Trial For MKC-1

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)... ERT (Nasdaq: ERES ), an...mpany,s President and CEO, and Keith Schneck, the ...heduled to present at the 21st Annual Piper Jaffra...r 1, 2009 in New York City, New York. ,, Intere...ng the Company,s corporate website at http://www....
(Date:11/25/2009)...v. 25 For many of the mi...he 27 million living with untreated hearing loss ...iologist Cindy Beyer. ,, Dr. Beyer, senior vice...a,s largest hearing care and hearing aids compan...ss, frustration, and social isolation, "which can ...
(Date:11/25/2009).... 25 /PRNewswire-Asia-FirstCall/ -- China Sky One,...pany") (Nasdaq: CSKI ), a,leading fully integrate...over-the-counter drugs in the People,s Republic of...ecently passed the Chinese National Institute for,...cts ("ICPBP") examination,for two of its new produ...
Breaking Medicine Technology:ERT to Present at the 21st Annual Piper Jaffray Health Care Conference on December 1, 2009 2For Millions With Untreated Hearing Loss, Holiday Season Can be Especially Difficult 2For Millions With Untreated Hearing Loss, Holiday Season Can be Especially Difficult 3China Sky One Medical, Inc. Achieved Progress in the Development of Two New Biological Testing Kits 2China Sky One Medical, Inc. Achieved Progress in the Development of Two New Biological Testing Kits 3MU researchers create drought conditions to unearth solutions 9444 1MU researchers create drought conditions to unearth solutions 9444 2Health Care Statement of Catholic Charities USA 53361 1AstraZeneca and the Artery Explorer Take California Residents on Virtual Journey Through the Arteries 53358 1AstraZeneca and the Artery Explorer Take California Residents on Virtual Journey Through the Arteries 53358 2AstraZeneca and the Artery Explorer Take California Residents on Virtual Journey Through the Arteries 53358 3AstraZeneca and the Artery Explorer Take California Residents on Virtual Journey Through the Arteries 53358 4AstraZeneca and the Artery Explorer Take California Residents on Virtual Journey Through the Arteries 53358 5
(Date:11/27/2009)...AN FRANCISCO, Nov. 27 Th...that Blair Lambert, CFO/COO, will present at the N...d at the May Fair Hotel in London, England, on Wed... To listen to a live broadcast of The Gymboree Cor...log on to www.gymboree.com, click on "Our Company"...
(Date:11/27/2009)..., NEUILLY-SUR-SEINE, France, Nov. 27 /PRNewswire/ ...essional cycling team dedicated to ethical sportin...ampions, announced today that it will become Team ...s Optical as a new sponsor of the team. Transition...daptive eyewear, offering the most advanced photoc...
(Date:11/27/2009)... XenaCare Holdings has announced that... Foundation, one of the largest nonprofit organiza...ealth education. , Delray...oldings, Inc. (OTCBB: XCHO), a company specializin...umer healthcare products, has announced today that...
(Date:11/27/2009)...s to bring unprecedented medical, economic burdens...althDay News) -- The number of people with diabete...the next 25 years, a new study predicts. , That...on people with the disease, up from 23.7 million t... people with diabetes will triple, the study also ...
(Date:11/27/2009)... Voyant Health™ announced today... licensed its TraumaCad Enterprise orthopedic temp...solution. , (PRWEB) Novem...ay that Spectrum Health (Grand Rapids, Michigan) h...mplating solution and its TraumaCad Extend workflo...
Breaking Medicine News(10 mins):Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 2Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 2Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 4Health News:Diabetes Cases Expected to Double in 25 Years 2Health News:Diabetes Cases Expected to Double in 25 Years 3Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 3
...ON, Sept. 28 - About a third of American,adults ta...n nearly every,case, the goal is better health, ev...s hope. The absence of benefit is one thing, but t...sk among,men using multivitamins, reports the Octo...
...anies, Church Team Up to Transport Goods to Peru, ... today,teamed up with its largest customer, DHL, t...goods provided by The Church of Jesus Christ of La...ds of,specially processed, ultra-high temperature ...
...URHAM, N.C. -- Determining the genetic profile of ...he crucial decision about which chemotherapy treat...rs from the Duke University Comprehensive Cancer C... chemotherapy drugs. , We were able to predict w...
...IEL, Israel, Sept. 28 The Russell,Investment Grou... ) that,there will be a float weight adjustment ef..., 2007 in the following indexes: Russell 2000,Russ...e Russell Small Cap Completeness Growth. About Pr...
...ement of William V. Corr Executive Director, Campa... Kids, WASHINGTON, Sept. 28 The following is ...or, Campaign for,Tobacco-Free Kids: Last night, t...ax to help fund the State Children,s Health Insura...
...ROSS, Ga., Sept. 28 Immucor, Inc.,(Nasdaq: BLUD ...nt-reagent,systems to the blood transfusion indust... first quarter earnings on Wednesday, October 3, 2...vestors,are invited to participate in this confere...
Other Medicine News:Health News:Excessive Multivitamin Use May Raise Risk for Prostate Cancer, from Harvard Men's Health Watch 2Health News:ASTAR Air Cargo, The Church of Jesus Christ of Latter-day Saints and DHL to Help Peruvian Earthquake Victims 2Health News:ASTAR Air Cargo, The Church of Jesus Christ of Latter-day Saints and DHL to Help Peruvian Earthquake Victims 3Health News:Genomic profiling of lung tumors helps doctors choose most effective treatment 2Health News:Genomic profiling of lung tumors helps doctors choose most effective treatment 3Health News:Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment 2Health News:President Bush Should Protect Kids, Not Big Tobacco By Signing Bill to Increase Cigarette Tax, Fund SCHIP 2Health News:Immucor Schedules First Quarter Earnings Release and Conference Call 2
OEC UroView 2800
Hydra Vision® Plus DR Urology System
...ect® Heavy Duty is a pressure relief mattress ...rapy specifically to the BariKare® Bed., ,IND...d 650 lbs., Large patients at risk or suffering fr...ic mattress that would benefit from a pressure rel...
...00 is a bariatric bed system which helps provide c... setting, ,INDICATIONS: ,Patients weighing up to ...ame accommodating one or two individuals, dependin...tal weight in excess of 1000 lbs. (including acces...
Medicine Products: